Researchers reported a mechanism linking doxorubicin chemotherapy to accelerated heart aging in male mice, with CD47—the “don’t eat me” protein—emerging as a driver of chemotherapy-induced senescence-like changes. The findings connect immune evasion biology with late-emerging cardiac effects known from anthracycline treatments. Separately, a review argues that NK cell senolytics represent a first serious test of a broader anti-aging concept: eliminating senescent cells that accumulate with age and can promote dysfunction. Together, the pieces reinforce a growing biomedical narrative: immune checkpoints and senescence biology may offer converging levers for long-term morbidity reduction after cancer therapy and during aging. For biotech leaders, the immediate implication is translational opportunity around senescence-targeting immunomodulators and checkpoint-pathway biology, with careful attention to tissue-specific safety.